MRNA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

67.740

Open

63.960

VWAP

64.14

Vol

24.08M

Mkt Cap

25.38B

Low

60.730

Amount

1.54B

EV/EBITDA(TTM)

--

Total Shares

396.79M

EV

20.81B

EV/OCF(TTM)

--

P/S(TTM)

11.25

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Show More

Events Timeline

(ET)

2026-06-18

16:30:00

Moderna's mRNA-1010 Vaccine Receives Unanimous Support from FDA Advisory Committee

2026-06-18

16:00:00

Moderna's mFLUSIVA Vaccine Receives Full FDA Approval

2026-06-18

15:00:00

FDA Advisers Say Moderna Flu Vaccine Benefits Outweigh Risks for Adults 65 and Older

2026-06-16 (ET)

2026-06-16

09:30:00

Jefferies Maintains Hold Rating on Moderna, Price Target $45

2026-06-16

09:30:00

FDA Holds Meeting to Discuss Moderna's mFlusiva Vaccine

2026-06-16

08:00:00

Moderna Adjusts Operating Model to Support Business Goals

2026-06-12 (ET)

2026-06-12

13:30:00

HHS Supports Development of Bundibugyo Ebola Vaccine

News

NASDAQ.COM

06-20NASDAQ.COM

PinnedModerna Reports 260% Revenue Growth in Q1, Expands mRNA Applications

Fool

PinnedModerna's Diversification Strategy Boosts Stock Recovery

Yahoo Finance

06-20Yahoo Finance

Moderna's Progress in Vaccine Diversification

seekingalpha

06-18seekingalpha

Moderna's Flu Vaccine Gains FDA Advisory Panel Support

stocktwits

06-18stocktwits

Moderna's mRNA Flu Vaccine Receives Key Support from Advisory Committee

Newsfilter

06-18Newsfilter

Moderna's Influenza Vaccine Receives FDA Advisory Support

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise

1 Buy

16 Hold

3 Sell

Hold

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

Jefferies

Hold

maintain

$45

AI Analysis

2026-06-18

New

Reason

Jefferies

Price Target

$45

AI Analysis

2026-06-18

New

maintain

Hold

Reason

Jefferies reiterated a Hold rating and $45 price target on Moderna after the FDA's Advisory Committee voted 9-0 in favor of a full approval for Moderna's mFLUSIVA mRNA seasonal flu vaccine for ages 50-64, and 9-0 in favor of accelerated approval in people aged 65 or older. Per the firm's analysis, FDA decisions in 2020-2025 aligned with AdCom recommendations 84% of the time, the analyst tells investors in a research note. The firm said, net-net, its confidence rises in an approval for ages 50+, though flu revenues may not occur until 2027. The firm models $750M of U.S. flu and flu/cocvid combo sales by 2030.

BofA

Underperform

maintain

$34

2026-06-16

Reason

BofA

Price Target

$34

2026-06-16

maintain

Underperform

Reason

BofA reviewed the VRBPAC briefing docs released this morning. Overall, the tone of the documents and proposed points of focus should foster some debate but look supportive for approval, the firm says. BofA sees the clinical profile for mFlusiva as mostly known and therefore expect VRBPAC to function more as a vote on regulatory acceptability rather than underlying data strength. Evidence gaps summarized in the documents include efficacy limited to one flu season, limited data in immunocompromised and frailer patients, safety data lacking for administration with other vaccines, and B/Victoria strain case accrual limited. The firm expects a positive VRBPAC result but maintains an Underperform rating on the stock with a price target of $34.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRNA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is 23.04, compared to its 5-year average forward P/E of -0.29. For a more detailed relative valuation and DCF analysis to assess Moderna Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.29

Current PE

23.04

Overvalued PE

14.64

Undervalued PE

-15.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.99

Current EV/EBITDA

-8.10

Overvalued EV/EBITDA

6.52

Undervalued EV/EBITDA

-12.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

6.63

Current PS

10.10

Overvalued PS

9.21

Undervalued PS

4.06

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what if I have $5000 to invest

Intellectia · 90 candidates

Region: USPrice: >= $-100.00Ema 20: >= -100News Driver: Positive

Ticker

Name

Market Cap$

Icecure Medical Ltd

17.96M

Uniqure NV

3.04B

Fathom Holdings Inc

36.39M

AstroNova Inc

219.65M

Allbirds Inc

48.26M

Euro Tech Holdings Company Ltd

11.64M

stocks to day trade that are safe

Intellectia · 7 candidates

Market Cap Category: large, midRsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Is Index Component: GSPC, NDXWeekly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Moderna Inc

20.98B

News Corp

17.06B

Dell Technologies Inc

159.53B

Norfolk Southern Corp

69.87B

News Corp

14.78B

Xcel Energy Inc

50.32B

trade analysis of top five gap upstocks

Intellectia · 61 candidates

Relative Vol: >= 1.50Gap Pattern: GapUpMoving Average Relationship: PriceAboveMA5, PriceAboveMA20

Ticker

Name

Market Cap$

Antelope Enterprise Holdings Ltd

6.19M

Rackspace Technology Inc

1.37B

Westrock Coffee Co

804.85M

Fluence Energy Inc

4.45B

Virax Biolabs Group Ltd

1.27M

Everspin Technologies Inc

632.85M

what stocks trending today?

Intellectia · 46 candidates

Region: USPrice Change Pct: >= $0.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceBelowMA5Is Trending: True

Ticker

Name

Market Cap$

Xerox Holdings Corp

205.32M

Skillz Inc

90.17M

Ginkgo Bioworks Holdings Inc

464.43M

Eli Lilly and Co

804.24B

Bakkt Inc

240.22M

Hyatt Hotels Corp

14.96B

Technical Analysis on vaccine

Intellectia · 6 candidates

Market Cap: >= 2.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchThemes: BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Biogen Inc

26.91B

Moderna Inc

21.65B

Illumina Inc

20.18B

Incyte Corp

19.29B

Exelixis Inc

11.08B

CRISPR Therapeutics AG

5.56B

Day trading picks

Intellectia · 115 candidates

Price: $5.00 - $100.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: $0.50 - $5.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Rigetti Computing Inc

6.58B

Redwire Corp

2.06B

Intuitive Machines Inc

5.98B

Dow Inc

25.62B

AXT Inc

4.59B

Sharplink Inc

1.58B

provide the best 3 stocks

Intellectia · 20 candidates

Price: $20.00 - $80.00List Exchange: XNYS, XNASIs Optionable: TrueOption Iv Rank: 50 - 80Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Intel Corp

309.42B

Verizon Communications Inc

201.52B

Comcast Corp

101.86B

Trade Desk Inc

9.81B

Coca-Cola Co

336.50B

PayPal Holdings Inc

41.37B

find specific stocks

Intellectia · 20 candidates

Price: $20.00 - $80.00List Exchange: XNYS, XNASIs Optionable: TrueOption Iv Rank: 50 - 80Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Intel Corp

309.42B

Verizon Communications Inc

201.52B

Coca-Cola Co

336.50B

Comcast Corp

101.86B

Boston Scientific Corp

91.07B

PayPal Holdings Inc

41.37B

us stocks and ETFs

Intellectia · 56 candidates

Region: USPrice: $10.00 - $150.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: $0.40 - $2.50Monthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Marvell Technology Inc

79.99B

Shopify Inc

165.07B

Ondas Inc

4.73B

Barrick Mining Corp

72.21B

Roblox Corp

41.93B

Moderna Inc

21.05B

what stock should I buy rn

Intellectia · 7 candidates

Price: $10.00 - $80.00List Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00Is Index Component: GSPC, NDXOne Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

LyondellBasell Industries NV

23.95B

Dow Inc

26.96B

Occidental Petroleum Corp

57.61B

MGM Resorts International

9.29B

Corteva Inc

53.63B

PayPal Holdings Inc

40.84B

Whales Holding MRNA

Sessa Capital IM, L.P.

Two Sigma Investments, LP

Y-Intercept (Hong Kong) Limited

Banque Pictet & Cie SA

Tang Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 63.96 USD — it has increased 3.5

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

What is the price predicton of MRNA Stock?

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is32.47 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 389.00M USD, increased 260.19

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -3.40 USD, increased 34.92

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 4700 emplpoyees as of June 22 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 25.38B USD.